A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model
Jiaqi Huang, Di Zhang, Yu Bai, Pamela B. Yang, Ligang Xing, Jinming Yu · Journal of Cancer · 2020
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2020
Abstract
Accumulated extracellular adenosine suppresses antitumor immunity via adenosine 2A receptor (A2AR).Blockade of A2AR with DZD2269 can inhibit phosphorylation of cAMP response element-binding protein mediated by adenosine analogue in vitro and in vivo.Irradiation can cause the release of adenosine and lead to a rapid increase in free extracellular adenosine in the tumour area.DZD2269, a novel A2AR Antagonism, induces incomplete antitumor responses in multiple syngeneic mouse tumour models.Combining DZD2269 with IR can induce a synergistic anticancer effect.IR increases the infiltration of various subtypes of T cells, including CD4+, CD8+ and Foxp3+ T cells, into the tumour area.Combining IR and DZD2269 improves the tumour immune microenvironment, leading to suppressed infiltration of regulatory T (Treg) cells and enhanced IFN-γ expression by tumour-infiltrating lymphocytes.The results support the use of A2AR antagonism with DZD2269 as a therapeutic strategy for monotherapy or combination therapy with IR.
Open the resolved locator · 10.7150/jca.43966
Metadata licence: OpenAlex metadata (CC0)